Published in J Thromb Haemost on October 01, 2007
Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. J Thromb Haemost (2009) 0.91
Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians. Arthritis Rheum (2013) 0.82
Relationship between VKORC1 single nucleotide polymorphism 1173C>T, bone mineral density & carotid intima-media thickness. Indian J Med Res (2013) 0.80
Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clin Pharmacol Ther (2012) 0.75
VKORC1 gene variation and venous thrombosis: 'another one bites the dust'? J Thromb Haemost (2007) 0.75
Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med (1995) 3.55
Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost (2010) 2.43
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost (2006) 2.17
D-dimer testing is useful to exclude deep vein thrombosis in elderly outpatients. J Thromb Haemost (2008) 2.08
The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. J Thromb Haemost (2014) 1.99
Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. J Thromb Haemost (2014) 1.98
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med (1997) 1.97
Detection of over 98% cystic fibrosis mutations in a Celtic population. Nat Genet (1992) 1.72
The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum Mol Genet (1996) 1.71
Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost (2010) 1.69
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther (2011) 1.67
The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet (1998) 1.67
Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet (2000) 1.65
Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost (2007) 1.57
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost (2006) 1.51
Left main intervention revisited: early and late outcome of PTCA and stenting. Cathet Cardiovasc Diagn (1997) 1.50
Two populations of endothelial cell antibodies cross-react with heparin. Lupus (1998) 1.43
Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet (1999) 1.41
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol (2009) 1.41
[Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: the preOVNI study GFPC 12-01]. Rev Mal Respir (2012) 1.39
Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J Med Genet (2000) 1.27
Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol (2007) 1.27
Visual pontocerebellar projections in the macaque. J Comp Neurol (1994) 1.21
Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet (1999) 1.20
Exclusion of anionic trypsinogen and mesotrypsinogen involvement in hereditary pancreatitis without cationic trypsinogen gene mutations. Scand J Gastroenterol (1999) 1.15
Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther (1997) 1.15
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost (2009) 1.15
Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology (2001) 1.13
Influence of age on the cost-effectiveness of diagnostic strategies for suspected pulmonary embolism. J Thromb Haemost (2007) 1.12
Synthesis and properties of europium-based phosphors on the nanometer scale: Eu2O3, Gd2O3:Eu, and Y2O3:Eu. J Colloid Interface Sci (2004) 1.10
Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology (2005) 1.08
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther (2012) 1.08
Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther (2001) 1.05
Identification of 12 novel mutations in the CFTR gene. Hum Mol Genet (1993) 1.05
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost (2011) 1.05
Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. J Thromb Haemost (2007) 1.03
Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res (1995) 1.02
Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.02
[Value of the head-up tilt test in the etiologic diagnosis of syncope]. Presse Med (1990) 1.01
HLA-Bw35 and mesangial IgA glomerulonephritis. N Engl J Med (1978) 0.98
Sensitivity of the denaturing gradient gel electrophoresis technique in detection of known mutations and novel Asian mutations in the CFTR gene. Hum Mutat (1997) 0.97
Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost (2006) 0.97
[Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients]. J Mal Vasc (2010) 0.96
Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther (2000) 0.96
Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost (2000) 0.96
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
Screening blood donations for viral genomes: multicenter study of real-time simulation using pooled samples on the model of hepatitis C virus RNA detection. Transfusion (1998) 0.95
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost (2009) 0.94
Volumetric or time-based capnography for excluding pulmonary embolism in outpatients? J Thromb Haemost (2009) 0.93
Corticopontine projection in the rat: the distribution of labelled cortical cells after large injections of horseradish peroxidase in the pontine nuclei. J Comp Neurol (1989) 0.93
Alcohol dependence is associated with reduced plasma and fundic ghrelin levels. Eur J Clin Invest (2008) 0.93
Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther (2010) 0.93
Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers. Hum Mutat (1996) 0.92
A combined analysis of the cystic fibrosis transmembrane conductance regulator: implications for structure and disease models. Mol Biol Evol (2001) 0.92
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis (2007) 0.91
Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther (1994) 0.91
TP53 gene mutation profile in esophageal squamous cell carcinomas. Cancer Res (1993) 0.91
Evaluation of a new, rapid, and quantitative D-Dimer test in patients with suspected pulmonary embolism. Am J Respir Crit Care Med (1998) 0.90
Identification of six novel mutations in the CFTR gene of patients from Bulgaria by screening the twenty seven exons and exon/intron boundaries using DGGE and direct DNA sequencing. Hum Mol Genet (1994) 0.90
Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project. Thromb Haemost (2001) 0.90
Assessment of coronary artery stents by 16 slice computed tomography. Heart (2005) 0.90
Zoonotic bacteria, antimicrobial use and antimicrobial resistance in ornamental fish: a systematic review of the existing research and survey of aquaculture-allied professionals. Epidemiol Infect (2011) 0.90
Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost (1998) 0.90
Aerobic and anaerobic contribution to Wingate test performance in sprint and middle-distance runners. Eur J Appl Physiol Occup Physiol (1995) 0.89
Psychological effect of exercise in women with breast cancer receiving adjuvant therapy: what is the optimal dose needed? Ann Oncol (2012) 0.89
HLA class II typing and idiopathic IgA nephropathy (IgAN): DQB1*0301, a possible marker of unfavorable outcome. Tissue Antigens (1995) 0.89
Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics (2001) 0.89
Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev (2010) 0.88
DGGE screening of PKD1 gene reveals novel mutations in a large cohort of 146 unrelated patients. Hum Genet (1999) 0.88
The therapeutic management of chronic pain in ambulatory care patients aged 65 and over in France: the S.AGES Cohort. Baseline data. J Nutr Health Aging (2013) 0.88
Novel mutations in the duplicated region of PKD1 gene. Eur J Hum Genet (2000) 0.88
CFTR mutations in the Algerian population. J Cyst Fibros (2007) 0.88
Prenatal detection of cystic fibrosis by ultrasonography: a retrospective study of more than 346 000 pregnancies. J Med Genet (2002) 0.88
Lactate kinetics during passive and partially active recovery in endurance and sprint athletes. Eur J Appl Physiol Occup Physiol (1996) 0.88
Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis. Clin Genet (2001) 0.88
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther (2007) 0.86
Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology (2007) 0.86
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost (2006) 0.86
Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost (2012) 0.86
Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc (2009) 0.86
Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies. J Lab Clin Med (1996) 0.86
Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects. J Nutr Health Aging (2010) 0.85
Caffeine increases maximal anaerobic power and blood lactate concentration. Eur J Appl Physiol Occup Physiol (1992) 0.85
Inheritance of a stable mutation in a family with early-onset disease. Nephron (2001) 0.85
Identification of 3 novel mutations (Y4236X, Q3820X, 11745+2 ins3) in autosomal dominant polycystic kidney disease 1 gene (PKD1). Hum Mutat (2000) 0.85
Accelerated hypertension associated with lupus anticoagulant and false-positive VDRL in systemic lupus erythematosus. Arthritis Rheum (1986) 0.85
Genotype analysis of adult cystic fibrosis patients. Hum Mol Genet (1993) 0.85